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Abstract:  36 
Despite numerous examples of the effects of the human gastrointestinal microbiome on drug  37 
efficacy and toxicity, there is often an incomplete understanding of the underlying mechanisms.  38 
Here, we dissect the inactivation of the cardiac drug digoxin by the gut Actinobacterium  39 
Eggerthella lenta. Transcriptional profiling, comparative genomics, and culture-based assays  40 
revealed a cytochrome-encoding operon up-regulated by digoxin, inhibited by arginine, absent in  41 
non-metabolizing E. lenta strains, and predictive of digoxin inactivation by the human gut  42 
microbiome. Pharmacokinetic studies using gnotobiotic mice revealed that dietary protein  43 
reduces the in vivo microbial metabolism of digoxin, with significant changes to drug  44 
concentration in the serum and urine. These results emphasize the importance of viewing  45 
pharmacology from the perspective of both our human and microbial genomes.   46 
  47 
One Sentence Summary:   48 
A microbial biomarker predicts digoxin inactivation by the human gut microbiome; studies in  49 
mice show that dietary protein prevents this biotransformation.  50 
  51 
Main Text:  52 
Humans are home to large and diverse microbial communities, the most abundant of which  53 
resides in the gastrointestinal tract. Recent studies have highlighted the clinical relevance of the  54 
biotransformations catalyzed by the human gut microbiome, including alterations to the  55 
bioavailability, activity, and toxicity of therapeutic drugs (1, 2). Although >40 drugs are  56 
metabolized by the gut microbiome, little is known about the underlying mechanisms. This  57 
knowledge is critical to enable the rational design of pharmaceutical or dietary interventions.  58 
The inactivation of the cardiac drug digoxin provides a promising starting point for  59 
understanding microbial drug metabolism. Digoxin and other cardiac glycosides have been  60 
widely used for hundreds of years to treat heart failure and arrhythmias. Therapeutic effects are  61 
accomplished indirectly when inhibition of the Na
+/K
+ ATPase in cardiac myocytes raises the  62 
intracellular Ca
2+ concentration (3). Digoxin has a narrow therapeutic range (0.5-2.0 ng/mL) (3),  63 
and some patients excrete the inactive digoxin metabolite, dihydrodigoxin, in which the lactone  64 
ring is reduced (fig. S1A) (4). This modification disrupts ring planarity, which is thought to shift  65   3 
positioning within the binding pocket of the Na
+/K
+ ATPase, resulting in decreased target  66 
affinity (5). Co-administration of broad spectrum antibiotics increases serum digoxin (4), and  67 
Eggerthella lenta reduces digoxin in vitro (6). Prior to this work, the molecular mechanism of  68 
digoxin reduction and the factors that alter microbial drug inactivation in vivo were unknown.  69 
We confirmed that E. lenta DSM2243, the type strain, reduces digoxin in vitro (7), and  70 
that arginine inhibits this reaction (Fig. 1A). The growth of E. lenta DSM2243 was stimulated by  71 
arginine supplementation (Fig. 1A,S2), indicative of using the arginine dihydrolase pathway for  72 
ATP (8). Citrulline (an intermediate upstream of ATP production) stimulated growth, whereas  73 
ornithine (an end product) did not (figs. S2,S3).   74 
E. lenta cultures were grown anaerobically in rich medium supplemented with low- and  75 
high-levels of arginine (0.25% and 1.25%, respectively) in the presence or absence of digoxin  76 
(10 µg/mL) and we performed RNA-Seq on the resultant cellular biomass (figs. S4-6, table S1).  77 
A two-gene operon was highly up-regulated after exposure to digoxin during exponential growth  78 
(>100-fold; Fig. 1B, tables S2,S3). These two genes, referred to here as the cardiac glycoside  79 
reductase (cgr) operon (gene labels: cgr1 and cgr2), encode proteins that are homologous to  80 
bacterial cytochromes and are therefore potentially capable of using digoxin as an alternative  81 
electron acceptor. Incubation of E. lenta with multiple cardiac glycosides and their reduced  82 
forms revealed that the cgr operon is broadly responsive to compounds with an α,β-unsaturated  83 
butyrolactone ring (figs. S7-9, table S5).   84 
Digoxin induction was increased in low arginine conditions during both exponential and  85 
stationary phase, relative to cultures exposed to high levels of arginine (fig. S10A,B). cgr  86 
induction by digoxin, and the growth phase-dependent effects exerted by arginine were  87 
confirmed on independent samples using qRT-PCR (Figs. 1C,S7C, table S4). Unlike arginine,  88 
ornithine did not repress cgr2 expression (fig. S11). These results are consistent with the  89 
hypothesis that arginine represses cgr operon expression, thereby inhibiting digoxin reduction.   90 
Next, we tested three strains of E. lenta (DSM2243, FAA 1-3-56, and FAA 1-1-60) (9,  91 
10), for digoxin reduction; the type strain was the sole strain capable of digoxin reduction in  92 
vitro (Fig. 1D). Comparative genomics revealed that the type strain was nearly indistinguishable  93 
from the other two strains using common marker genes (fig. S12). Reciprocal BLASTP  94 
comparisons of all protein-coding sequences of the three fully sequenced E. lenta strains  95 
revealed that the type strain shared 79.4% and 90.5% of its proteome with strains FAA 1-3-56  96   4 
and FAA 1-1-60, respectively (fig. S12). The cgr operon was unique to the type strain (table  97 
S6); furthermore, the two non-reducing E. lenta strains were missing three genomic loci which  98 
were also up-regulated by digoxin, and are predicted to encode membrane transporters for the  99 
uptake of small molecules and glycosides (fig. S13). Arginine did not significantly decrease the  100 
expression level of these transporters (fig. S14).  101 
Strain-level variation provides an explanation for the difficulties in predicting  102 
dihydrodigoxin levels in cardiac patients by the presence or absence of E. lenta (6, 11). We used  103 
qPCR to measure the relative abundance of the cgr operon to the E. lenta 16S rRNA gene (the  104 
“cgr ratio”) in microbial community DNA from 20 unrelated healthy people, along with ex vivo  105 
digoxin reduction assays. The results stratified our cohort into low reducers (12.82±10.68%  106 
reduction; n=6) and high reducers (96.25±7.69% reduction; n=14) (Fig. 2A). The cgr ratio was  107 
significantly increased for the high reducers (1.058±0.562) when compared to low reducers  108 
(0.425±0.582; P<0.05, Student’s t test) (Fig. 2B,S15). Linear regression of reduction efficiency  109 
with the cgr ratio revealed a significant correlation (R
2=0.22, P<0.05), whereas the abundance of  110 
E. lenta failed to predict the extent of reduction (R
2=0.06, P=0.30). The optimal cgr ratio cutoff  111 
(0.6) predicted digoxin reduction efficiency with a sensitivity of 86%, specificity of 83%, and  112 
precision of 92%.   113 
Co-culture of E. lenta with the fecal microbiome enhanced the efficiency of digoxin  114 
reduction. Each low-reducing fecal samples was incubated with the type (reducing) and FAA 1- 115 
3-56 (non-reducing) strains of E. lenta. The communities incubated with the type strain reduced  116 
more digoxin (95.39±2.41%) than the type strain alone (68.91±7.70%; P<0.05, Mann-Whitney  117 
test) (Fig. 2C). The cgr ratio was significantly elevated after co-culture (Fig. 2D), and was  118 
tightly linked to reduction efficiency (R
2=0.74, P<0.0001). An explanation for the observed  119 
microbial synergy is that the fastidious growth of E. lenta is promoted by growth factors supplied  120 
by the gut microbiota, a phenomena that is known to impact the metabolism of environmental  121 
pollutants by soil microbial communities (12), along with competition for arginine that boosts  122 
digoxin reduction by E. lenta. Consistent with these hypotheses, the abundance of the E. lenta  123 
type strain was significantly increased in the presence of a complex microbial community  124 
(1.6e6±4.8e5 vs. 1.8e5±8.4e3 in isolation; P<0.05, Mann-Whitney test), and arginine  125 
supplementation suppressed the reduction of digoxin during co-culture (fig. S16).   126   5 
  Diet could also explain inter-individual variations in digoxin reduction. In vitro growth of  127 
E. lenta showed that while arginine stimulated cell growth, it decreased cgr operon expression,  128 
and prevented the conversion of digoxin to dihydrodigoxin (Figs. 1A,C,S10). These observations  129 
led us to hypothesize that increased consumption of dietary protein, and the corresponding  130 
increase in arginine, would inhibit the in vivo reduction of digoxin by E. lenta. Germ-free adult  131 
male Swiss-Webster mice were colonized with the type strain prior to being fed diets differing  132 
only in the amount of total protein (n=5 mice/group; tables S7,S8; fig. S17A). E. lenta colonized  133 
mice on both diets (fig. S18A), and exhibited high levels of expression of the cgr operon (fig.  134 
S18B). Quantification of serum and urine digoxin (7) revealed significant increases on the high  135 
protein diet, indicative of suppressed digoxin reduction by E. lenta (Fig. 3A,B). These trends  136 
were also consistent with fecal analysis of samples from each group of mice 4-16 hours  137 
following digoxin administration (Fig. 3). We also confirmed that the high protein diet  138 
significantly elevated the level of amino acids in the distal small intestine (7), resulting in a fold  139 
increase of 1.71±0.06 (p<0.001, Wilcoxon test; tables S9,10).  140 
We controlled for the indirect effects of host diet and colonization that might alter  141 
digoxin pharmacokinetics irrespective of reduction by E. lenta. Germ-free mice were colonized  142 
with either the digoxin-reducing type strain or the non-reducing FAA 1-3-56 strain, and  143 
subsequently fed the same two diets (fig. S17B). As seen before, we detected colonization with  144 
both strains, high cgr operon expression, and elevated serum and urine digoxin on the high  145 
protein diet for mice colonized with the type strain (Figs. 3C,D,S18C,D). Diet did not  146 
significantly impact the serum or urine digoxin levels of mice colonized with the non-reducing  147 
strain (Fig. 3C,D). Serum digoxin was significantly lower in mice colonized with the type strain  148 
on the 0% protein diet, relative to those colonized with the non-reducing strain (4.91±1.56  149 
ng/mL vs. 13.8±1.25; P<0.01, Student’s t test, Fig. 3C). Together, these results suggest that the  150 
increased level of free amino acids available to E. lenta inhibited the activity of the cgr operon,  151 
increasing the bioavailability of digoxin.   152 
An expanded model of digoxin pharmacokinetics is now emerging: colonization by  153 
distinct strains of E. lenta, microbial interactions, and host diet act together to influence drug  154 
levels (fig. S19). Follow-up studies in cardiac patients are necessary to determine if rapid qPCR- 155 
based biomarker assessments of the gut microbiome can guide dosage regimes. It may also be  156 
possible to provide dietary guidelines or supplements that prevent microbial drug metabolism.  157   6 
More broadly, our results emphasize that a comprehensive view of pharmacology includes the  158 
structure and activity of our resident microbial communities, and a deeper understanding of their  159 
interactions with each other, with their host habitat, and with the nutritional milieu of the  160 
gastrointestinal tract.  161 
  162 
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Figure legends  230 
  231 
Fig. 1. Discovery of a bacterial operon induced by digoxin. (A) Arginine stimulates the  232 
growth of E. lenta DSM2243 in vitro while blocking the reduction of digoxin. Maximum OD600  233 
(solid line; values are the mean±sem; n=3) and digoxin % reduction efficiency (dashed line;  234 
values are the mean; n=2) after 48 hours of growth. (B) RNA-Seq profiles of the cardiac  235 
glycoside reductase (cgr) operon are shown with/without digoxin during exponential growth in  236 
medium containing low/high arginine. The height is proportional to the natural log of the number  237 
of unambiguous sequencing reads mapped to each base. (C) cgr2 transcription as determined by  238 
qRT-PCR. Asterisks indicate statistical significance by Student’s t test (P<0.05). Horizontal lines  239 
are the mean; n=2-3. (D) Identification of 2 strains of E. lenta incapable of reducing digoxin.  240 
Values are the mean±sem; n=3. ND=no reduction detected.   241 
  242 
Fig. 2. A microbial biomarker predicts the inactivation of digoxin. (A) Liquid  243 
chromatography/mass spectrometry (LC/MS) was used to quantify digoxin reduction in the fecal  244 
microbiomes of 20 unrelated individuals. (B) The cgr ratio was significantly different between  245 
low and high reducers. Data represent qPCR using the cgr2 gene, and E. lenta specific 16S  246 
rDNA primers (table S4). (C) Five low reducing fecal microbial communities were incubated for  247 
five days in the presence or absence of E. lenta DSM2243 or FAA 1-3-56. LC/MS was used to  248 
quantify the completion of digoxin reduction. Supplementation with the non-reducing strain of E.  249 
lenta did not significantly affect digoxin reduction efficiency. (D) The cgr ratio was obtained for  250 
each of the low reducing microbial communities post incubation. Outliers were identified using  251 
Grubbs’ test (P<0.01) and removed. Values are the mean±sem. Points in A,B represent  252 
biological replicates. Asterisks indicate statistical significance by Student’s t test (*=P<0.05;  253 
***=P<0.001; ****=P<0.0001).   254 
  255 
Fig. 3. Dietary protein blocks the inactivation of digoxin. Serum (A) and urinary (B) digoxin  256 
levels from the type strain experiment. Fecal digoxin levels showed a consistent trend: the mean  257 
area under the curve was 6.226 ng digoxin*h/mL in germ-free mice, 3.576 for mice on the 0%  258 
protein diet, and 6.364 for mice on the 20% protein diet. Serum (C) and urinary (D) digoxin  259 
levels from each group. Digoxin levels were quantified by ELISA (7). Values are the mean±sem.  260   9 
Asterisks indicate statistical significance by Student’s t test (*=P<0.05; **=P<0.01). n=4-5  261 
mice/group. NS=not significant.   262 
  263 
  264 
  265 